4-Chlorobenzoyl berbamine, a novel berbamine derivative, induces apoptosis in multiple myeloma cells through the IL-6 signal transduction pathway and increases FOXO3a-Bim expression

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 425-432

  Shen, Jia Kun ^a,b   Du, Hua Ping ^c   Ma, Qiuling ^a   Yang, Min ^a   Wang, Yun Gui ^a   Jin, Jie ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shangrao Prefectural People's Hospital   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Berbamine derivative; FOXO3a; IL 6; IL 6 receptor; Multiple myeloma

Indexed keywords

4 CHLOROBENZOYL BERBAMINE; BERBAMINE; BIM PROTEIN; CASPASE 3; CASPASE 8; CASPASE 9; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN MM1.R; CELL STRAIN MM1.S; CELL STRAIN RPMI 8226; CELL STRAIN U266; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IC 50; MULTIPLE MYELOMA; MYELOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZYLISOQUINOLINES; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; FORKHEAD TRANSCRIPTION FACTORS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; INTERLEUKIN-6; MEMBRANE PROTEINS; MULTIPLE MYELOMA; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84878171867     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2431     Document Type: Article

References (30)

1. Barillé-Nion S, Barlogie B, Bataille R, et al: Advances in biology and therapy of multiple myeloma. Hematology Am Soc Hematol Educ Program 2003: 248-278, 2003. doi: 10.1182/asheducation-2003.1.248.
2. Kuehl WM and Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2: 175-187, 2002. (Pubitemid 37328787)
3. Richardson PG, Mitsiades C, Schlossman R, Munshi N and Anderson K: New drugs for myeloma. Oncologist 12: 664-689, 2007. (Pubitemid 47036203)
4. Lentzsch S, O'Sullivan A, Kennedy RC, et al: Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 119: 4608-4613, 2012.
5. Palumbo A, Attal M and Roussel M: Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 17: 1253-1263, 2011.
6. Lauta VM: A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications. Cancer 97: 2440-2452, 2003.
7. Trikha M, Corringham R, Klein B and Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665, 2003. (Pubitemid 37323267)
8. Hideshima T, Nakamura N, Chauhan D and Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 20: 5991-6000, 2001. (Pubitemid 32955041)
9. Ramgolam V, Ang SG, Lai YH, Loh CS and Yap HK: Traditional Chinese medicines as immunosuppressive agents. Ann Acad Med Singapore 29: 11-16, 2000. (Pubitemid 30252141)
10. Küpeli E, Ko?ar M, Ye?ilada E, Hüsnü K and Ba?er C: A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish Berberis species. Life Sci 72: 645-657, 2002. (Pubitemid 35441232)
11. Zhao XY, He ZW, Wu D and Xu RZ: Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivin-mediated pathway. Chin Med J (Engl) 120: 802-806, 2007. (Pubitemid 46767828)
12. Wang GY, Zhang JW, Lu QH, Xu RZ and Dong QH: Berbamine induces apoptosis in human hepatoma cell line SMMC7721 by loss in mitochondrial transmembrane potential and caspase activation. J Zhejiang Univ Sci B 8: 248-255, 2007.
13. Xu R, Dong Q, Yu Y, et al: Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res 30: 17-23, 2006. (Pubitemid 41654699)
14. Li BY, Fu B, Zhao YL and Li WH: Effects of berbamine on intracellular calcium concentration in cultured HeLa cells. Zhongguo Yao Li Xue Bao 20: 1011-1014, 1999.
15. Du HP, Shen JK, Yang M, et al: 4-Chlorobenzoyl berbamine induces apoptosis and G2/M cell cycle arrest through the PI3K/Akt and NF-κB signal pathway in lymphoma cells. Oncol Rep 23: 709-716, 2010.
16. Cui Y, Xu M, Mao J, Ouyang J, Xu R and Yu Y: Synthesis of berbamine acetyl glycosides and evaluation of antitumor activity. Eur J Med Chem 54: 867-872, 2012.
17. Vermes I, Haanen C, Steffens-Nakken H and Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51, 1995.
18. Dorée M and Hunt T: From Cdc2 to Cdk1: when did the cell cycle kinase join its cyclin partner? J Cell Sci 115: 2461-2464, 2002. (Pubitemid 34778063)
19. Galea CA, Wang Y, Sivakolundu SG and Kriwacki RW: Regulation of cell division by intrinsically unstructured proteins: intrinsic flexibility, modularity, and signaling conduits. Biochemistry 47: 7598-7609, 2008. (Pubitemid 352019491)
20. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A and Nishida E: Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 410: 215-220, 2001. (Pubitemid 32216594)
21. Klein B, Zhang XG, Lu ZY and Bataille R: Interleukin-6 in human multiple myeloma. Blood 85: 863-872, 1995.
22. Kovacs E: Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model. Sc World J 6: 888-898, 2006.
23. Guo Y, Xu F, Lu T, Duan Z and Zhang Z: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38: 904-910, 2012.
24. Petros AM, Olejniczak ET and Fesik SW: Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta 1644: 83-94, 2004. (Pubitemid 38281265)
25. Willis SN, Fletcher JI, Kaufmann T, et al: Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859, 2007.
26. Hübner A, Barrett T, Flavell RA and Davis RJ: Multisite phosphorylation regulates Bim stability and apoptotic activity. Mol Cell 30: 415-425, 2008. (Pubitemid 351672377)
27. Brunet A, Bonni A, Zigmond MJ, et al: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-868, 1999. (Pubitemid 29165088)
28. Barreyro FJ, Kobayashi S, Bronk SF, Werneburg NW, Malhi H and Gores GJ: Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem 282: 27141-27154, 2007. (Pubitemid 47501972)
29. Modur V, Nagarajan R, Evers BM and Milbrandt J: FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928-47937, 2002. (Pubitemid 36159321)
30. Burgering BM and Kops GJ: Cell cycle and death control: long live Forkheads. Trends Biochem Sci 27: 352-360, 2002. (Pubitemid 34756518)